Trial · NCT03702829
24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
NCT03702829, Phase 2, Terminated, Brigham and Women's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients. Trials, record NCT03702829. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03702829
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
- NCT number
- NCT03702829
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 31 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Amyloidosis
- Interventions
- Inotersen
- First posted
- 2018-10-11
- Last updated
- 2026-02-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Systolic strain imaging by echocardiographic | Month 6 | The primary echocardiographic parameter to be measured will be longitudinal left ventricular (LV) strain (units = % LV longitudinal shortening) as compared to baseline. |
| Secondary | Systolic strain evaluation by echocardiography | Month 12 | The primary echocardiographic parameter measured will be longitudinal left ventricular (LV) strain (units = %). |
| Secondary | Systolic strain evaluation by echocardiography | Month 18 | The primary echocardiographic parameter measured will be longitudinal left ventricular (LV) strain (units = %). |
| Secondary | Systolic strain evaluation by echocardiography | Month 24 | The primary echocardiographic parameter measured will be longitudinal left ventricular (LV) strain (units = %). |
| Secondary | LV mass measurement by Cardiac MRI (cMRI) (units = grams) | Month 6 | measurement of LV mass by CMR mapping techniques |
| Secondary | LV mass measurement by Cardiac MRI (cMRI) (units = grams) | Month 12 | measurement of LV mass by CMR mapping techniques |
| Secondary | LV mass measurement by Cardiac MRI (cMRI) (units = grams) | Month 24 | measurement of LV mass by CMR mapping techniques |
| Secondary | ECV-extracellular volume by Cardiac MRI (cMRI) (unit=percentage) | Month 6 | measurement of extracellular volume by CMR T1 mapping techniques |
| Secondary | ECV-extracellular volume by Cardiac MRI (cMRI) (unit=percentage) | Month 12 | measurement of extracellular volume by CMR T1 mapping techniques |
| Secondary | ECV-extracellular volume by Cardiac MRI (cMRI) (unit=percentage) | Month 24 | measurement of extracellular volume by CMR T1 mapping techniques |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03702829
GET https://conductscience.org/api/trials/v1/NCT03702829/registered